POLR2I

Across TCGA pan-cancer cohorts, POLR2I mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POLR2I data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLR2I mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated POLR2I expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where POLR2I mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	1.000	0.655	<.001	24	view →
LUAD	DFS	Median	All	0.752	0.513	.003	19	view →
LSCC	DFS	Median	II,III,IV	0.904	0.668	.026	7	view →
UCEC	OS	Median	All	0.914	0.982	.036	6	view →
HNSC	OS	Tertile	II,III,IV	0.768	0.929	.022	6	view →
CCRCC	DFS	Tertile	All	0.584	0.876	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POLR2I–PDAC (OS)

Open the PDAC breakdown →